SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

Clinical and Translational Oncology

Volumn 15, Issue 12, 2013, Pages 991-995

  Maurel, J ^a   Gravalos C ^b   Rivera, F ^c   Vera, R ^d   Gonzalez Flores E ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Adjuvant; Cancer; Colorectal; Evidence based recommendations

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ARTICLE; BLOOD CELL COUNT; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG SAFETY; FOLLOW UP; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; MEDICAL HISTORY; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PROCTITIS; RECTUM CANCER; TUMOR BIOPSY;

ALGORITHMS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; EVIDENCE-BASED PRACTICE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT;

EID: 84888198705     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1083-4     Document Type: Article

References (25)

1. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Chichester: Wiley-Blackwell; 2009.
2. Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet. 2001;357:497-504.
3. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005;97:219-25.
4. Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, Haglind E, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Colon Cancer Laparoscopic or Open Resection Study Group. Lancet Oncol. 2009;10(1):44-52.
5. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-16.
6. Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O'Connell MJ, Yothers G. A phase III trial comparing 5FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol. 2008;26(15S):LBA4005.
7. Haller D, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Adjuvant treatment with capecitabine and oxaliplatin (XELOX) in stage III colon cancer. Berlin: ESMO/ECCO Presidential Session III; 2009.
8. McCleary NA, Meyerhardt J, Green E, Yothers G, de Gramont A, Van Cutsem E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol. 2009;27:15s (suppl; abstr 4010).
9. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059-64.
10. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-704.
11. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456-61.
12. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117-25.
13. Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, et al. A phase III trial comparing FOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009;27(15S):LBA4.
14. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-19.
15. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253:711-9.
16. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-46.
17. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40.
18. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-23.
19. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620-5.
20. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579-88.
21. Roh MS, Yothers GA, O'Connell MJ, Beart RW, Pitot NC, Shields AF et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. In: Proceedings of ASCO 3503; 2011.
22. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng CA, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770-6.
23. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010;21:1743-50.
24. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;1:CD002200.
25. Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, et al. American Cancer Society; US Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130(6):1865-71.